cliffwatch

ubrogepant · Abbvie · NDA 211765

Ubrelvy

Earliest generic entry, as listed · earliest of 2 marketed strengths
22 Dec 2041

Blocked by patent: US 11717515, US 11857542, US 12070450, US 12194030, US 12194030, US 12329750. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.

Listed patents · 17 unexpired

PatentClaimsExpires
US 11717515use U-367722 Dec 2041
US 11857542use U-378622 Dec 2041
US 12070450use U-399222 Dec 2041
US 12194030use U-412222 Dec 2041
US 12194030use U-412122 Dec 2041
US 12329750use U-421322 Dec 2041
US 10117836product30 Jan 2035
US 11925709product30 Jan 2035
US 12168004product30 Jan 2035
US 12220408product30 Jan 2035
US 12310953product30 Jan 2035
US 12458632product30 Jan 2035
US 12458633product30 Jan 2035
US 8912210substance, product23 Dec 2033
US 8754096substance, product, use U-271719 Jul 2032
US 9499545substance, product, use U-271810 Nov 2031
US 9833448use U-271810 Nov 2031

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • 25 Oct 2026Generic tentatively approved · 211765-001
  • 25 Oct 2026Generic tentatively approved · 211765-001

Products covered · 2

NDA · productFormStrengthListed expiry
211765 · 001 · RLDtablet, oral50MG22 Dec 2041
211765 · 002 · RLDtablet, oral100MG22 Dec 2041